- Lobe Sciences Limited (LOBE) has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS
- The agreement with Dr. Natbony is for the study of the tolerability and efficacy of Lobe’s proprietary psilocin compound L-130 in patients suffering from cluster headaches (CH)
- Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines
- Integrative Headache Medicine of New York (IHMNY) is a multidisciplinary institute dedicated to treating patients with complex headache and facial pain disorders
- Lobe Sciences Ltd. (LOBE) was unchanged at $0.04 at 12:34 ET
Lobe Sciences Limited (LOBE) has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS.
The agreement with Dr. Natbony, Founder and Medical Director of Integrative Headache Medicine of New York, is for the study of the tolerability and efficacy of Lobe’s proprietary psilocin compound L-130, in patients suffering from cluster headaches (CH).
“This is an exciting opportunity to evaluate L-130’s effect on the intensity, frequency, and duration of these debilitating headaches,” said Philip J. Young, Chairman and Chief Executive Officer.
“One in every thousand people suffers from this condition, also called ‘Suicide Headaches,’ due to the pain, frequency of attacks, and lack of effective treatments,” he added.
Dr. Natbony is a board-certified neurologist and fellowship-trained headache specialist. She has dedicated her career to treating chronic headache and facial pain disorders, including cluster headaches.
Lobe anticipates that Dr. Natbony will file a physician-initiated IND. When cleared by the US FDA, she can begin dosing CH patients with L-130 to evaluate safety, tolerability, and efficacy.
“We are very excited to evaluate the impact of Lobe’s psilocin compound, L-130, in treating these devastating headaches,” stated Dr. Natbony.
“Since L-130 is the active metabolite of psilocybin, it appears to be an efficient way of delivering non-psychedelic doses of psilocin with potentially better bioavailability and consistency,” she added.
Cluster headache is a rare but severe primary headache disorder, impacting 0.1 per cent of the general population, and characterized by excruciating one-sided pain around the eye.
Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines.
Integrative Headache Medicine of New York (IHMNY), founded and directed by Dr. Lauren R. Natbony, is a comprehensive, multidisciplinary institute dedicated to treating patients with complex headache and facial pain disorders.
Lobe Sciences Ltd. (LOBE) was unchanged at $0.04 at 12:34 ET.